Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth

Conclusion: The stapled peptide targeting the main interface between CDK4 and cyclin D provides promising therapeutic perspectives for patients with lung cancer.

Source: Theranostics - July 3, 2020 Category: Molecular Biology Authors: Celine Bouclier, Matthieu Simon, Guillaume Laconde, Morgan Pellerano, Sebastien Diot, Sylvie Lantuejoul, Benoit Busser, Laetitia Vanwonterghem, Julien Vollaire, V é ronique Josserand, Baptiste Legrand, Jean-Luc Coll, Muriel Amblard, Amandine Hurbin, May Tags: Research Paper Source Type: research